The Committee will discuss Cidara Therapeutics New Drug Application (NDA) 217417 for Rezafungin Lyophilized powder for injection for treatment of candidemia and invasive candidiasis in adults in a virtual meeting being held on January 24 at 9 am. Webcast Link
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CDTX:
- FDA Antimicrobial Drugs Advisory Committee to hold a virtual meeting
- Cidara Therapeutics nominates first oncology candidate from Cloudbreak platform
- Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform
- Cidara Therapeutics announces issuance of first U.S. patent for CD388
- Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388
